health1 month ago
Xenon Halts Depression Trials Over Psychosis Reports, Files Epilepsy NDA
Xenon Pharmaceuticals has voluntarily paused enrollment in its phase 3 depression trials for azetukalner after observing adverse events, including psychosis, in a small number of patients. The company continues treating existing participants but plans to adjust dosing to improve tolerability. Despite the setback, Xenon filed for FDA approval for the drug in focal seizures, citing robust safety data from epilepsy studies. Analysts view the pause as temporary and unrelated to a broader class safety issue, though the stock dropped 26% on the news.